250 related articles for article (PubMed ID: 22173161)
1. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.
Zhu Q; Zou L; Jagavelu K; Simonetto DA; Huebert RC; Jiang ZD; DuPont HL; Shah VH
J Hepatol; 2012 Apr; 56(4):893-9. PubMed ID: 22173161
[TBL] [Abstract][Full Text] [Related]
2. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide promotes angiogenesis in mice model of HCC by stimulating hepatic stellate cell activation via TLR4 pathway.
Lu Y; Xu J; Chen S; Zhou Z; Lin N
Acta Biochim Biophys Sin (Shanghai); 2017 Nov; 49(11):1029-1034. PubMed ID: 29036356
[TBL] [Abstract][Full Text] [Related]
4. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
[TBL] [Abstract][Full Text] [Related]
5. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
Fujinaga Y; Kawaratani H; Kaya D; Tsuji Y; Ozutsumi T; Furukawa M; Kitagawa K; Sato S; Nishimura N; Sawada Y; Takaya H; Kaji K; Shimozato N; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759852
[TBL] [Abstract][Full Text] [Related]
6. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells.
Teratani T; Tomita K; Suzuki T; Oshikawa T; Yokoyama H; Shimamura K; Tominaga S; Hiroi S; Irie R; Okada Y; Kurihara C; Ebinuma H; Saito H; Hokari R; Sugiyama K; Kanai T; Miura S; Hibi T
Gastroenterology; 2012 Jan; 142(1):152-164.e10. PubMed ID: 21995947
[TBL] [Abstract][Full Text] [Related]
7. Effect of Rifaximin on Hepatic Fibrosis in Bile Duct-ligated Rat Model.
Shin SK; Kwon OS; Lee JJ; Park YH; Choi CS; Jeong SH; Choi DJ; Kim YS; Kim JH
Korean J Gastroenterol; 2017 Nov; 70(5):239-246. PubMed ID: 29161793
[TBL] [Abstract][Full Text] [Related]
8. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
Douhara A; Moriya K; Yoshiji H; Noguchi R; Namisaki T; Kitade M; Kaji K; Aihara Y; Nishimura N; Takeda K; Okura Y; Kawaratani H; Fukui H
Mol Med Rep; 2015 Mar; 11(3):1693-700. PubMed ID: 25421042
[TBL] [Abstract][Full Text] [Related]
9. Bile duct ligation-induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cell-deficient Kit
Hargrove L; Kennedy L; Demieville J; Jones H; Meng F; DeMorrow S; Karstens W; Madeka T; Greene J; Francis H
Hepatology; 2017 Jun; 65(6):1991-2004. PubMed ID: 28120369
[TBL] [Abstract][Full Text] [Related]
10. Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells.
Tomita K; Teratani T; Suzuki T; Shimizu M; Sato H; Narimatsu K; Usui S; Furuhashi H; Kimura A; Nishiyama K; Maejima T; Okada Y; Kurihara C; Shimamura K; Ebinuma H; Saito H; Yokoyama H; Watanabe C; Komoto S; Nagao S; Sugiyama K; Aosasa S; Hatsuse K; Yamamoto J; Hibi T; Miura S; Hokari R; Kanai T
J Hepatol; 2014 Jul; 61(1):98-106. PubMed ID: 24657401
[TBL] [Abstract][Full Text] [Related]
11. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
[TBL] [Abstract][Full Text] [Related]
12. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses.
Guo J; Loke J; Zheng F; Hong F; Yea S; Fukata M; Tarocchi M; Abar OT; Huang H; Sninsky JJ; Friedman SL
Hepatology; 2009 Mar; 49(3):960-8. PubMed ID: 19085953
[TBL] [Abstract][Full Text] [Related]
13. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
14. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
15. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis.
Taura K; De Minicis S; Seki E; Hatano E; Iwaisako K; Osterreicher CH; Kodama Y; Miura K; Ikai I; Uemoto S; Brenner DA
Gastroenterology; 2008 Nov; 135(5):1729-38. PubMed ID: 18823985
[TBL] [Abstract][Full Text] [Related]
16. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.
Huang HC; Wang SS; Hsin IF; Chang CC; Lee FY; Lin HC; Chuang CL; Lee JY; Hsieh HG; Lee SD
Hepatology; 2012 Jul; 56(1):248-58. PubMed ID: 22290687
[TBL] [Abstract][Full Text] [Related]
18. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension.
Jalan R; De Chiara F; Balasubramaniyan V; Andreola F; Khetan V; Malago M; Pinzani M; Mookerjee RP; Rombouts K
J Hepatol; 2016 Apr; 64(4):823-33. PubMed ID: 26654994
[TBL] [Abstract][Full Text] [Related]
19. Infection as a Trigger for Portal Hypertension.
Steib CJ; Schewe J; Gerbes AL
Dig Dis; 2015; 33(4):570-6. PubMed ID: 26159275
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin extra domain-A promotes hepatic stellate cell motility but not differentiation into myofibroblasts.
Olsen AL; Sackey BK; Marcinkiewicz C; Boettiger D; Wells RG
Gastroenterology; 2012 Apr; 142(4):928-937.e3. PubMed ID: 22202457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
